Shreyaskumar Patel, Mary Louise Keohan, M. Wasif Saif, Daniel Rushing, Luis Baez, Kevie Feit, Robert DeJager and Sibyl Anderson Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy Cancer 107
Article first published online: 15 NOV 2006 | DOI: 10.1002/cncr.22334
TZT-1027, a novel antimitotic agent, was tested in patients with soft-tissue sarcomas. In all, 21% of patients experienced stable disease but no objective responses were noted. The drug was safe and well tolerated.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.